Welcome to HealthLinx Limited
HealthLinx is a biomarker and diagnostic development company with a focus on the development of novel blood based diagnostics for targeted diseases that have
un-met market need.
The Ovarian Cancer Program has completed a phase II biomarker trial in 2008 that screened 150 diseased samples and 212 normal samples with the outcome being the development of OvPlex™ an ovarian cancer diagnostic targeting symptomatic women. Interim results from the multi-centre multi-national trial was
released to the market in late 2011 where over 740 samples were used in a global recruitment campaign involving clinicians in Australia, Singapore and the United Kingdom.
HealthLinx will be recognised as a leader in delivering diagnostic applications to improve health outcomes.
OvPlex™ is a panel of five biomarkers secreted in women’s blood and includes CA125. Statistical significance was achieved demonstrating OvPlex™ is a better performing diagnostic than CA125 as
interpreted by an independent biostatistician. A second, larger 1150 patient multinational, multisite study is underway. Data analysed to date are derived from a sample set comprising 222 women
with malignant epithelial ovarian cancer, 53 women with confirmed borderline ovarian tumours, 223 women with benign gynecological conditions and 244 apparently healthy controls.
Independent analysis by Emphron Informatics Pty Ltd, has confirmed that OvPlex™ displays a robust, statistically significant increase in performance over CA125 alone for the correct diagnosis of
benign, borderline and early stage malignant ovarian cancers.
OvPlex™ is currently distributed in Australia, Singapore, Malaysia and the United Kingdom.
Diagnostics
|
|
|
Unlike the therapeutics’ market, where it can take up to 15 years and US$1billion to get a drug from discovery to the market, a diagnostic will usually
take less than a third of that time and less than 10% of the cost.
read more |
|
Analyst Research
|
|
|
|
Independent analyst research reports on HealthLinx Limited.
read more
|
|
|
